Detalhe da pesquisa
1.
Patient survey on cancer genomic medicine in Japan under the national health insurance system.
Cancer Sci
; 115(3): 954-962, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273803
2.
Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.
Semin Cancer Biol
; 86(Pt 2): 386-395, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35569741
3.
Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy.
Cancer Sci
; 114(2): 630-639, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36285515
4.
Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.
Cancer Sci
; 114(7): 3041-3049, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165760
5.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Cancer Sci
; 114(2): 606-618, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169649
6.
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Br J Cancer
; 129(12): 2003-2013, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731022
7.
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Cancer Immunol Immunother
; 72(8): 2613-2621, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062033
8.
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
Future Oncol
; 19(22): 1515-1521, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577772
9.
Comprehensive screening for drugs that modify radiation-induced immune responses.
Br J Cancer
; 126(12): 1815-1823, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184156
10.
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
Cancer Immunol Immunother
; 71(3): 737-746, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34389874
11.
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
Cancer Immunol Immunother
; 71(2): 387-398, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180007
12.
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant.
Eur J Clin Pharmacol
; 78(4): 613-621, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35039908
13.
First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status.
Future Oncol
; 18(3): 291-300, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758637
14.
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).
Future Oncol
; 18(5): 523-531, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034503
15.
Performance of Japanese patients in registrational studies.
Jpn J Clin Oncol
; 52(1): 53-64, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978326
16.
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
Cancer Sci
; 112(4): 1534-1544, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462883
17.
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
Br J Cancer
; 124(5): 925-932, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33250511
18.
Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Jpn J Clin Oncol
; 51(7): 1114-1122, 2021 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881137
19.
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
Lancet Oncol
; 21(6): 843-850, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502444
20.
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
Oncologist
; 25(4): e668-e674, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31771990